These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Matricellular proteins in intrahepatic cholangiocarcinoma. Sirica AE Adv Cancer Res; 2022; 156():249-281. PubMed ID: 35961702 [TBL] [Abstract][Full Text] [Related]
24. Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers. Pei L; Liu Y; Liu L; Gao S; Gao X; Feng Y; Sun Z; Zhang Y; Wang C Mol Cancer; 2023 Feb; 22(1):29. PubMed ID: 36759842 [TBL] [Abstract][Full Text] [Related]
25. Cancer-associated fibroblasts in neoadjuvant setting for solid cancers. Gu Y; Chen Q; Yin H; Zeng M; Gao S; Wang X Crit Rev Oncol Hematol; 2024 Jan; 193():104226. PubMed ID: 38056580 [TBL] [Abstract][Full Text] [Related]
26. Cancer-associated fibroblasts promote tumor cell growth via miR-493-5p in intrahepatic cholangiocarcinoma. Toshida K; Itoh S; Harada N; Morinaga A; Yugawa K; Tomiyama T; Kosai-Fujimoto Y; Tomino T; Kurihara T; Nagao Y; Morita K; Oda Y; Yoshizumi T Cancer Sci; 2023 Mar; 114(3):937-947. PubMed ID: 36369960 [TBL] [Abstract][Full Text] [Related]
27. Taking a Full Snapshot of Cancer Biology: Deciphering the Tumor Microenvironment for Effective Cancer Therapy in the Oncology Clinic. Dzobo K OMICS; 2020 Apr; 24(4):175-179. PubMed ID: 32176591 [TBL] [Abstract][Full Text] [Related]
28. Cancer-associated fibroblasts and the tumor microenvironment in non-small cell lung cancer. Suzuki J; Tsuboi M; Ishii G Expert Rev Anticancer Ther; 2022 Feb; 22(2):169-182. PubMed ID: 34904919 [TBL] [Abstract][Full Text] [Related]
29. The tumor microenvironment as driver of stemness and therapeutic resistance in breast cancer: New challenges and therapeutic opportunities. Mehraj U; Ganai RA; Macha MA; Hamid A; Zargar MA; Bhat AA; Nasser MW; Haris M; Batra SK; Alshehri B; Al-Baradie RS; Mir MA; Wani NA Cell Oncol (Dordr); 2021 Dec; 44(6):1209-1229. PubMed ID: 34528143 [TBL] [Abstract][Full Text] [Related]
30. Immune checkpoint inhibitors as mediators for immunosuppression by cancer-associated fibroblasts: A comprehensive review. Eskandari-Malayeri F; Rezaei M Front Immunol; 2022; 13():996145. PubMed ID: 36275750 [TBL] [Abstract][Full Text] [Related]
31. MiR-206 suppresses the deterioration of intrahepatic cholangiocarcinoma and promotes sensitivity to chemotherapy by inhibiting interactions with stromal CAFs. Yang R; Wang D; Han S; Gu Y; Li Z; Deng L; Yin A; Gao Y; Li X; Yu Y; Wang X Int J Biol Sci; 2022; 18(1):43-64. PubMed ID: 34975317 [No Abstract] [Full Text] [Related]
32. Breaking Physical Barrier of Fibrotic Breast Cancer for Photodynamic Immunotherapy by Remodeling Tumor Extracellular Matrix and Reprogramming Cancer-Associated Fibroblasts. Qiu ZW; Zhong YT; Lu ZM; Yan N; Kong RJ; Huang JQ; Li ZF; Nie JM; Li R; Cheng H ACS Nano; 2024 Apr; 18(13):9713-9735. PubMed ID: 38507590 [TBL] [Abstract][Full Text] [Related]
33. Sequentially targeting and intervening mutual Polo-like Kinase 1 on CAFs and tumor cells by dual targeting nano-platform for cholangiocarcinoma treatment. Zhou Y; Xu L; Wang Z; Liu H; Zhang X; Shu C; Zhang M; Wang T; Xu X; Pu X; He J; Wang P; Qiu Y; Xu G; Zou X; Zhu Y; Wang L Theranostics; 2022; 12(8):3911-3927. PubMed ID: 35664077 [No Abstract] [Full Text] [Related]
34. Cancer-Associated Fibroblast Heterogeneity: A Factor That Cannot Be Ignored in Immune Microenvironment Remodeling. Chen PY; Wei WF; Wu HZ; Fan LS; Wang W Front Immunol; 2021; 12():671595. PubMed ID: 34305902 [TBL] [Abstract][Full Text] [Related]
35. Breast Cancer CAFs: Spectrum of Phenotypes and Promising Targeting Avenues. Elwakeel E; Weigert A Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769066 [TBL] [Abstract][Full Text] [Related]
36. CAF-immune cell crosstalk and its impact in immunotherapy. Maia A; Schöllhorn A; Schuhmacher J; Gouttefangeas C Semin Immunopathol; 2023 Mar; 45(2):203-214. PubMed ID: 36480035 [TBL] [Abstract][Full Text] [Related]
37. The role of tumour microenvironment: a new vision for cholangiocarcinoma. Chen Z; Guo P; Xie X; Yu H; Wang Y; Chen G J Cell Mol Med; 2019 Jan; 23(1):59-69. PubMed ID: 30394682 [TBL] [Abstract][Full Text] [Related]
38. Diversity and Biology of Cancer-Associated Fibroblasts. Biffi G; Tuveson DA Physiol Rev; 2021 Jan; 101(1):147-176. PubMed ID: 32466724 [TBL] [Abstract][Full Text] [Related]
39. Cancer-associated fibroblasts (CAFs) and tumor-associated macrophages (TAMs); where do they stand in tumorigenesis and how they can change the face of cancer therapy? Tajaldini M; Saeedi M; Amiriani T; Amiriani AH; Sedighi S; Mohammad Zadeh F; Dehghan M; Jahanshahi M; Zanjan Ghandian M; Khalili P; Poorkhani AH; Alizadeh AM; Khori V Eur J Pharmacol; 2022 Aug; 928():175087. PubMed ID: 35679891 [TBL] [Abstract][Full Text] [Related]
40. SERPINE1: Role in Cholangiocarcinoma Progression and a Therapeutic Target in the Desmoplastic Microenvironment. Czekay RP; Higgins CE; Aydin HB; Samarakoon R; Subasi NB; Higgins SP; Lee H; Higgins PJ Cells; 2024 May; 13(10):. PubMed ID: 38786020 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]